SecBot SecBot
EFFECT ·Filed Mar 2, 2026

SYRE

Spyre Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed8mo ago SEC9999999995-26-000695
IPO/offering going effective
Actionable Insight • Neutral

Monitor for future prospectus supplements that will disclose actual offering terms, timing, and size. Shelf registrations allow flexibility but create potential dilution overhang.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$42.49
T+0 close · Mar 2, 2026 · via day close
Latest settled
+73.33%
T+60 · $73.65
Vs SPY
+64.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $42.49entry
  2. T+1 · 9mo ago −5.70%α −4.78% · $40.07
  3. T+5 · 8mo ago −3.34%α −2.13% · $41.07
  4. T+20 · 8mo ago +6.90%α +14.83% · $45.42
  5. T+60 · 6mo ago +73.33%α +64.01% · $73.65
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to issue unspecified securities from time to time. This is a routine capital markets update with no immediate financial impact.

Key Facts

  • Form EFFECT filed for Spyre Therapeutics, Inc. (SYRE)
  • Effectiveness date: February 27, 2026
  • Underlying registration is Form S-3 (shelf registration)
  • No specific offering size, pricing, or securities type disclosed
  • Company previously known as Aeglea BioTherapeutics, Inc.

Financial Impact

Not specified

dilutioncapital_structure

Risk Factors

  • Future issuance could lead to shareholder dilution
  • Market perception of equity overhang may pressure stock price

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-000695
Document: 9999999995-26-000695-index.html9999999995-26-000695
Document: 9999999995-26-000695.txt9999999995-26-000695

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (11h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026